



## The Bavaria Study INNORYOS

DEAR VALUED CUSTOMER,

We are pleased to share some exciting news with you: A recent comparative clinical study has confirmed that INNORYOS® once again proves its effectiveness and quality.

The study was designed to analyze the efficacy and safety of INNORYOS® 2.2% over a 6-month period in terms of pain, stiffness and function compared to a standard product of animal origin (Synvisc) in patients with knee osteoarthritis (OA).

The key results speak for themselves:



**Comprehensive  
symptom relief**

INNORYOS® effectively reduced pain, improved joint function, and decreased stiffness in OA patients.



**Superior mobility  
improvement**

INNORYOS® showed significantly better results in reducing joint stiffness compared to the control group.



**Significant and fast pain  
reduction**

Already 2 weeks post-injection, 78% of INNORYOS® patients reported a positive treatment effect.

Find out more about the study's results and what they mean for you!

[PUBLICATION](#)

We thank you for your trust in INNORYOS® and look forward to continuing to support you with the best solutions for innovative osteoarthritis management.

Best regards,  
your **ALBOMED** team

If you have any questions, please feel free to contact us at any time.

[CONTACT](#)



ALBOMED GmbH | Hildebrandstr. 11 | 90592 Schwarzenbruck | Germany